Iachetta, Francesco
Bonelli, Candida
Romagnani, Alessandra
Zamponi, Raffaella
Tofani, Lorenzo
Farnetti, Enrico
Nicoli, Davide
Damato, Angela
Banzi, Maria
Casali, Bruno
Pinto, Carmine
Article History
Received: 29 November 2018
Revised: 20 February 2019
Accepted: 21 February 2019
First Online: 12 March 2019
Competing interests
: C.P. has participated in consulting or/and as advisory boards and has received honoraria from BMS, MSD, Bayer, Astra-Zeneca, Lilly, Servier, Merck, and Tesaro. A.D. has received honoraria from Servier. M.B. has received honoraria from BMS, Merck, Novartis. The remaining authors declare no competing interests.
: All participants provided written consent. AUSL IRCCS di Reggio Emilia biobank has approval from the local Ethics Committee (CE di Reggio Emilia) and that this study was approved by Area Vasta Emilia NORD Ethics Committee (CE AVEN). The study was performed in accordance with the Declaration of Helsinki.
: All data are available at Reggio Emilia Cancer Center for consultation.
: This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).